Thus, amplification of the PRKAA1 gene may be being selected for in TP53-mutant tumours because it can compensate for the lack of p53 and protect the tumour cells against genotoxic stresses that might otherwise kill them. The gene discussed is PRKAA1; the disease is neoplasm.